Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | HTR1B | P28222 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.32 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183876 | 0.89 | TP53 (0.33) | HTR1AHTR1BDRD2HTR2CHRH1 | |
| SCHEMBL20183535 | 0.88 | MAPT (0.33) | HTR1AHTR1BPDE4DMCHR1DRD2 | |
| SCHEMBL20788152 | 0.85 | AR (0.35) | ARSIGMAR1HTR1AHTR1BCTSS | |
| SCHEMBL20183765 | 0.83 | HTR6 (0.36) | HTR1BDRD2USP2ALDH1A1MAPT | |
| SCHEMBL20354296 | 0.81 | ALDH1A1 (0.37) | CTSSMEN1USP2ALDH1A1MAPT | |
| SCHEMBL20183589 | 0.73 | TP53 (0.33) | HTR1AHTR1BMCHR1DRD2 | |
| SCHEMBL20183667 | 0.72 | RAC2 (0.41) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL20183850 | 0.72 | KDM4E (0.40) | KCNH2MEN1USP2ALDH1A1MAPT | |
| SCHEMBL20183769 | 0.72 | DRD2 (0.34) | HTR1AHTR1BPDE4DMCHR1DRD2 | |
| SCHEMBL20788158 | 0.72 | LYN (0.39) | HTR1AMCHR1DRD2PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3327004-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | FUJIFILM CORPORATION (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| US-10633343-B2 | — | — | 2020-04-28 | — | — | US | disclosed |
| EP-3563851-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORPORATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | FUJIFILM CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| WO-2018124180-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | 富士フイルム株式会社 | 2018-07-05 | — | — | WO | disclosed |
| EP-3327004-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Fujifilm Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | BRD4, BRD1, BRD3 | AR 1020/4885SIGMAR1 3166/4885HTR1A 3200/4885 |
| US-10696637-B2 | Nitrogen-containing heterocyclic compound | CXCL10, CCL5, CXCR3 | AR 3628/4885SIGMAR1 913/4885HTR1A 2410/4885 |
| US-20190314360-A1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | BRD4, BRD1, BRD3 | AR 1020/4885SIGMAR1 3166/4885HTR1A 3200/4885 |
| US-20190077761-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CXCL10, CCL5, CXCR3 | AR 3628/4885SIGMAR1 913/4885HTR1A 2410/4885 |
| US-10633343-B2 | — | CXCL10, CCL5, CXCR3 | AR 3651/4885SIGMAR1 1375/4885HTR1A 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.